

Antoinette R Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6173939/publications.pdf>

Version: 2024-02-01

16
papers

831
citations

933447

10
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1355
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 49-58.	2.3	2
2	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 385-395.	3.1	5
3	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 629-636.	7.0	15
4	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 721-735.	2.3	5
5	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 85-97.	10.7	64
6	Targeted Treatment of Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 50-58.	2.0	7
7	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1442-1453.	4.1	38
8	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	5.9	58
9	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 393-407.	1.8	14
10	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	2.5	22
11	Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. , 2020, , .		4
12	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1587-1601.	10.7	80
13	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	7.1	285
14	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	329.8	203
15	Personalizing aromatase inhibitor therapy in patients with breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 70, 47-55.	7.7	27
16	Tumor mutational load in gynecological and breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 44-44.	1.6	2